|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 185.87 USD | +0.05% |
|
+0.47% | -11.37% |
| 12-02 | Icon survey reveals increasing clinical trial startup delays | RE |
| 12-02 | Icon plc Announces Results of Its Latest Industry Survey | CI |
| Capitalization | 14.19B 12.2B 11.43B 10.65B 19.68B 1,277B 21.4B 134B 51.62B 603B 53.27B 52.13B 2,206B | P/E ratio 2025 * |
28.8x | P/E ratio 2026 * | 19.4x |
|---|---|---|---|---|---|
| Enterprise value | 17.21B 14.8B 13.86B 12.92B 23.87B 1,549B 25.96B 162B 62.61B 732B 64.61B 63.23B 2,675B | EV / Sales 2025 * |
2.13x | EV / Sales 2026 * | 2.06x |
| Free-Float |
99.29% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: ICON Public Limited Company
| 1 day | +0.05% | ||
| 1 week | +0.47% | ||
| Current month | +0.47% | ||
| 1 month | +16.80% | ||
| 3 months | +6.28% | ||
| 6 months | +33.61% | ||
| Current year | -11.37% |
| 1 week | 174.13 |  | 191.15 |
| 1 month | 154.12 | | 191.15 |
| Current year | 125.1 | | 228.28 |
| 1 year | 125.1 | | 228.28 |
| 3 years | 125.1 | | 347.72 |
| 5 years | 125.1 | | 347.72 |
| 10 years | 62.31 | | 347.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 52 | 2024-09-30 | |
Tom O'Leary
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Administrative Officer | 50 | 2016-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
John Climax
CHM | Chairman | 72 | 2002-10-31 |
Ciaran Murray
CHM | Chairman | 62 | 2017-02-28 |
Stephen Cutler
BRD | Director/Board Member | 64 | 2015-11-24 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 0.91% | 4 M€ | +20.34% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.05% | +0.47% | -14.53% | -5.60% | 14.19B | |
| +0.63% | -1.33% | +5.59% | +19.87% | 47.37B | |
| +0.41% | -1.81% | +11.46% | +8.74% | 38.46B | |
| -2.56% | -5.20% | +57.04% | +66.98% | 35.73B | |
| +0.38% | -1.24% | +11.14% | +19.30% | 27.23B | |
| +0.61% | -7.48% | +56.37% | +165.22% | 15.44B | |
| +1.48% | +2.42% | +65.68% | +229.77% | 15.4B | |
| +0.43% | -1.63% | +51.98% | - | 13.64B | |
| -0.16% | -1.27% | +114.33% | +113.82% | 13.23B | |
| -1.51% | -3.24% | +54.47% | +71.23% | 12.55B | |
| Average | -0.01% | -2.03% | +41.35% | +76.59% | 23.32B | |
| Weighted average by Cap. | -0.07% | -2.15% | +32.70% | +57.40% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.08B 6.94B 6.5B 6.06B 11.2B 727B 12.18B 76.07B 29.37B 343B 30.31B 29.66B 1,255B | 8.13B 6.98B 6.54B 6.1B 11.26B 731B 12.25B 76.53B 29.55B 345B 30.5B 29.85B 1,263B |
| Net income | 556M 478M 448M 418M 771M 50.08B 839M 5.24B 2.02B 23.65B 2.09B 2.04B 86.48B | 726M 624M 585M 545M 1.01B 65.37B 1.1B 6.84B 2.64B 30.88B 2.73B 2.67B 113B |
| Net Debt | 3.02B 2.6B 2.43B 2.27B 4.19B 272B 4.56B 28.46B 10.99B 128B 11.34B 11.1B 470B | 2.52B 2.17B 2.03B 1.89B 3.49B 227B 3.8B 23.74B 9.17B 107B 9.46B 9.26B 392B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 185.87 $ | +0.05% | 905,324 |
| 25-12-04 | 185.77 $ | -1.07% | 1,654,494 |
| 25-12-03 | 187.78 $ | +2.53% | 1,031,248 |
| 25-12-02 | 183.14 $ | +1.91% | 912,765 |
| 25-12-01 | 179.71 $ | -2.86% | 1,340,479 |
Delayed Quote Nasdaq, December 05, 2025 at 04:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ICLR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition